Earnings ·
Adagio Medical Holdings reported a net loss of $6.7 million, or $(0.30) per share, for the quarter ended June 30…
ADGMAdagio Medical Holdings, Inc.
Adagio Medical Holdings reported a net loss of $6.7 million, or $(0.30) per share, for the quarter ended June 30, 2026, compared to a $3.9 million loss in the prior year period. Cash and cash equivalents stood at $7.7 million as of June 30, 2026. The company announced pivotal results from its 209-patient FULCRUM-VT trial, demonstrating an 84% freedom from ICD shock at six months and a promising safety profile with only 2.4% major adverse events. Adagio also submitted a Premarket Approval application to the FDA for its vCLAS Ventricular Ablation System and treated the first patient in Europe using its next-generation vCLAS Ultra catheter under Expanded Access authorization. The company operates in the medical device industry, developing and commercializing catheter ablation technologies for cardiac arrhythmias.